Thorazine: The Drug That Redefined Psychiatry

See how the introduction of thorazine to the market changed the face of psychiatry practice.

When Thorazine was introduced in 1955, it was hailed for producing a "chemical lobotomy."

Related Videos
Esther Ellen Freeman, MD, PhD: How COVID-19 Is Affecting Skin Differently in 2023
Megan Noe, MD, MPH: Dermatologists Join the Vaccine Discussion
Berdazimer Gel Provides Complete Molluscum Clearance in 30% of Patients in 12 Weeks
Ester Del Duca, MD: Molecular Phenotype Differences in African Eczema Patients
John Harris, MD, PhD: Advancing Vitiligo Care After Ruxolitinib Cream
Megan Noe, MD, MPH: Navigating Vaccines, COVID-19 Boosters with Dermatology Patients
John Harris, MD, PhD: Year 1 of Ruxolitinib Cream for Vitiligo
Caitlin Treuting: Medical Photography Grows in Pediatric Dermatology
Alberto Pappo, MD: Why Pediatric Melanoma Diagnosis Is In Flux
Jan Wehkamp, MD, PhD: Expanding the Studies of Ustekinumab for IBD
Related Content

FDA Grants 501(k) Clearance for PTSD Self-Neuromodulation Tool

March 21st 2023

John J. Miller, MD: A New Era For Psychiatric Medications

August 18th 2022

FDA Will Not Hold Advisory Meeting for MDD, PPD Drug Application

March 8th 2023

Ardythe Morrow, PhD: The Connection Between Gut Bacteria and Psychiatric Disorders

March 29th 2022

Aripiprazole Augmentation Improves Remission Rates for Treatment Resistant Depression

March 7th 2023

New Research Seeks Explanation of Antidepressant Placebo Effect

March 3rd 2023

FDA Grants 501(k) Clearance for PTSD Self-Neuromodulation Tool

March 21st 2023

John J. Miller, MD: A New Era For Psychiatric Medications

August 18th 2022

FDA Will Not Hold Advisory Meeting for MDD, PPD Drug Application

March 8th 2023

Ardythe Morrow, PhD: The Connection Between Gut Bacteria and Psychiatric Disorders

March 29th 2022

Aripiprazole Augmentation Improves Remission Rates for Treatment Resistant Depression

March 7th 2023

New Research Seeks Explanation of Antidepressant Placebo Effect

March 3rd 2023

FDA Grants 501(k) Clearance for PTSD Self-Neuromodulation Tool

March 21st 2023

John J. Miller, MD: A New Era For Psychiatric Medications

August 18th 2022

FDA Will Not Hold Advisory Meeting for MDD, PPD Drug Application

March 8th 2023

Ardythe Morrow, PhD: The Connection Between Gut Bacteria and Psychiatric Disorders

March 29th 2022

Aripiprazole Augmentation Improves Remission Rates for Treatment Resistant Depression

March 7th 2023

New Research Seeks Explanation of Antidepressant Placebo Effect

March 3rd 2023
© 2023 MJH Life Sciences

All rights reserved.